References
- Cancer research U.K Demographic facts for the world population. http://info.cancerresearchik.org/cancerstats/world/ demographics/index.htm.
- Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol 2011; 12: 1249-57. https://doi.org/10.1016/S1470-2045(11)70040-7
- Puts MT, Costa-Lima B, Monette J, et al., Medication problems in older, newly diagnosed cancer patients in Canada: how common are they? A prospective pilot study. Drugs Aging 2009; 26: 519-536. https://doi.org/10.2165/00002512-200926060-00008
- Hanigan MH, Dela Cruz BL, Thompson DM, et al., Use of prescription and nonprescription medications and supplements by cancer patients during chemotherapy: questionnaire validation. J Oncol Pharm Pract 2008; 14: 123-130. https://doi.org/10.1177/1078155208090624
- Riechelmann RP, Tannock IF, Wang L, et al., Potential Drug Interactions and Duplicate Prescriptions Among Cancer Patients. J Natl Cancer Inst. 2007; 99: 592-600. https://doi.org/10.1093/jnci/djk130
- Micromedex Drugdex (TM) (Thomson, Green wood, co, USA)
- Cashman J, Wright J, Ring A. The treatment of comorbidities in older patients with metastatic cancer. Support Care Cancer 2010; 18: 651-655. https://doi.org/10.1007/s00520-010-0813-1
- Koh Y, Kutty FB, Li SC. Drug-related problems in hospitalized patients on polypharmacy: the influence of age and gender. Ther Clin Risk Manag 2005; 1(1): 39-48. https://doi.org/10.2147/tcrm.1.1.39.53597
- Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23(8): 1296-1310. https://doi.org/10.1016/S0149-2918(01)80109-0
- Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf 2007; 30(10): 911-918. https://doi.org/10.2165/00002018-200730100-00009
- Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review J Am Acad Nurse Pract 2005; 17: 123-132. https://doi.org/10.1111/j.1041-2972.2005.0020.x
- Goldberg RM, Mabee J, Chan L, et al., Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 1996; 14(5): 447-450.
- Maggiore RH, Gross CP, Hurria A. Polypharmacy in older adults with cancer. Oncologist 2010; 15: 507-522. https://doi.org/10.1634/theoncologist.2009-0290
- Yap KY, Kuo EY, Lee JJ, et al., An onco-infomatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: an overview of the OncoRx project, Support Care Cancer 2009; 10: 1011-1019.
- Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother 2008; 42: 1017-1025. https://doi.org/10.1345/aph.1L037
- Lee HJ, Kang MK, Ko JH, et al., Analysis of Chemotherapy Prescribing Errors Detected by Pharmacists. Kor J Clin Pharm 2010; 20(2): 120-7.
- JY Lee, KH Choi, YS Cho, et al., The Benefit of Pharmacists' intervention on self-medications and discharge orders in the cardiology ward. J Kor Soc Health-Syst Pharm 2009; 26 (4): 356-361.
- Joo EH, Joh HN, Seo SM, et al., Survery on the Polypharmacy for the Outpatients in General Hospital. J Kor Soc Health-Syst Pharm 1997; 14(2): 129-134.
- National Prescribing Service Limited and Palliative Care Australia. Achieving quality use of medicines in the community for palliative and end of life care: A consultation report. Sydney: National Prescribing Service Ltd, 2009.
- C R Goh. Minimising Polypharmacy-a Challenge in Palliative Care. Singapore Med J 2002; 43(6): 273-275.
- Koh NY, Koo WH. Polypharmacy in palliative care: can it be reduced? Singapore Med J 2002; 43(6): 279-283.